Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Immunovant | Mind Blowing Facts

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

MarketBeat

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022

Upgrades

Benzinga

Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year

Immunovant Inc (NASDAQ:IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED). Immunovant expects to initiate its Phase 3 TED program in 2H of 2022 and is expected to enroll about 100 subjects for each trial. Topline…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Immunovant: Q3 Earnings Insights

Immunovant (NASDAQ:IMVT) reported its Q3 earnings results on Friday, February 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

417,901 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.